Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma

Clinical Epigenetics

Table 1 Clinical factors and HOXD10 methylation in 117 cases of HCC samples

Clinical factor	No.	HOXD10 methylation status		*P value
Clinical factor	No.	Unmethylated n = 27 (23.1%)	Methylated n = 90 (76.9%)	*P value
Age (year)				0.799
< 60	80	19	61
≥ 60	37	8	29
Gender				0.248
Male	101	21	80
Female	16	6	10
HBV infection				0.762
Yes	85	19	66
No	32	8	24
Liver cirrhosis				0.093
Yes	88	17	71
No	29	10	19
Tumor size (cm)				0.231
≤ 5	37	6	31
> 5	80	21	59
Number of lesions				0.681
1	92	22	70
≥ 1	25	5	20
Differentiation				0.044*
Well	8	4	4
Moderate	74	19	55
Poor	35	4	31
TNM stage				0.377
Stage I + stage II	52	14	38
Stage III + stage IV	65	13	52
Lymph node metastasis				0.867
Negative	112	26	86
Positive	5	1	4
Vessel cancerous embolus				0.049*
Negative	87	24	63
Positive	30	3	27

ISSN: 1868-7083